Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.